AbstractObjectivesTo evaluate whether low‐dose belantamab mafodotin (B‐MAF) dosing results in lower toxicity and better overall outcome.MethodsWe retrospectively evaluated nine consecutive patients treated with low‐dose (1.9 mg/kg) B‐MAF.ResultsThe median age was 70 years. Most patients were penta‐refractory. Ocular toxicity was observed in 77.7%. Adverse events resulting in treatment delays were recorded in 9 out of 124 cycles being given. Overall response rate was 66% (6/9), and all responding patients achieved very good partial response or better. Within a median follow‐up of 12 (range 0.5–13.8) months, median progression‐free survival and overall survival were 14 (CI95% 6–22) and 20 (95%CI 0–41) months, respectively.ConclusionLow‐dose B‐MAF regimen showed high‐efficacy and low‐toxicity profile.